文献速递造血干细胞移植与细胞治疗

移植后结局的生物标志物

Biomarkers for posttransplantation outcomes.
PubMed 文献 · Blood · 2018-04-05

该综述概述了异基因造血干细胞移植后并发症,尤其急性移植物抗宿主病(aGVHD)的候选血液生物标志物,重点介绍依据2014年美国国立卫生研究院(NIH)共识标准、通过大规模蛋白质组学平台发现并在至少2个独立队列中验证的标志物,并梳理从发现到临床应用的路径。

要点

  • 血液生物标志物可用于aGVHD的诊断、预后分层及治疗反应预测。
  • 重点标志物需经大规模蛋白质组学发现并在至少2个独立队列验证。
  • 这类血液检测尚未可用于常规临床诊疗。

核心结论

  • 血液生物标志物在aGVHD诊断、预后分层及治疗反应预测方面有前景,但尚未常规用于临床。

研究设计与样本

  • 综述,聚焦经大规模蛋白质组学平台发现、并按2014年美国国立卫生研究院(NIH)共识标准在至少2个独立队列中验证的候选生物标志物。

主要发现

  • 已知的移植结局决定因素(受者年龄、合并症、预处理强度、供者来源、供受者HLA相容性、预处理方案、移植后GVHD预防)对结局的预测不完整。
  • 血液生物标志物已被识别并验证为有前景的诊断试验、预后试验(分层aGVHD未来发生)和预测试验(预测GVHD治疗反应及非复发死亡)。

关键数值与推荐

  • 重点生物标志物需依据2014年美国国立卫生研究院(NIH)共识标准,在至少2个独立队列中、用同一可重复检测方法验证,且样本量充分。

临床怎么用

  • 这些血液检测尚未可用于常规临床诊疗。

局限性

  • 这类血液检测尚未可用于常规临床诊疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

During the last decade, the development of biomarkers for the complications seen after allogeneic hematopoietic stem cell transplantation has expanded tremendously, with the most progress having been made for acute graft-versus-host disease (aGVHD), a common and often fatal complication. Although many factors are known to determine transplant outcome (including the age of the recipient, comorbidity, conditioning intensity, donor source, donor-recipient HLA compatibility, conditioning regimen, posttransplant GVHD prophylaxis), they are incomplete guides for predicting outcomes. Thanks to the advances in genomics, transcriptomics, proteomics, and cytomics technologies, blood biomarkers have been identified and validated for us in promising diagnostic tests, prognostic tests stratifying for future occurrence of aGVHD, and predictive tests for responsiveness to GVHD therapy and nonrelapse mortality. These biomarkers may facilitate timely and selective therapeutic intervention. However, such blood tests are not yet available for routine clinical care. This article provides an overview of the candidate biomarkers for clinical evaluation and outlines a path from biomarker discovery to first clinical correlation, to validation in independent cohorts, to a biomarker-based clinical trial, and finally to general clinical application. This article focuses on biomarkers discovered with a large-scale proteomics platform and validated with the same reproducible assay in at least 2 independent cohorts with sufficient sample size according to the 2014 National Institutes of Health consensus on biomarker criteria, as well as on biomarkers as tests for risk stratification of outcomes, but not on their pathophysiologic contributions, which have been reviewed recently.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Paczesny S. Biomarkers for posttransplantation outcomes. Blood. 2018. PMID: 29622549. doi:10.1182/blood-2018-02-791509

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。